Listed

GRUPO SIMEC, S.A.B. de C.V.: Form 20-F for the period ended Dec 31, 2022

Filed with the SEC on May 1, 2023 and accepted by EDGAR at May 1, 2023, 16:58 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2022-01-01 to 2022-12-31MXN 54.16bnifrs-full:Revenue
Cost of revenue12 months2022-01-01 to 2022-12-31MXN 39.68bnifrs-full:CostOfSales
Gross profit12 months2022-01-01 to 2022-12-31MXN 14.48bnifrs-full:GrossProfit
Income tax12 months2022-01-01 to 2022-12-31MXN 3.30bnifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2022-01-01 to 2022-12-31−MXN 7.86bnifrs-full:ProfitLossAttributableToOwnersOfParent
Basic EPS12 months2022-01-01 to 2022-12-31MXN 17.00ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2022-01-01 to 2022-12-31MXN 8.95bnifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2022-01-01 to 2022-12-31MXN 1.70bnifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2022-12-31MXN 21.55bnifrs-full:CashAndCashEquivalents
Current assetsAt period end2022-12-31MXN 43.52bnifrs-full:CurrentAssets
Total assetsAt period end2022-12-31MXN 67.63bnifrs-full:Assets
Current liabilitiesAt period end2022-12-31MXN 15.15bnifrs-full:CurrentLiabilities
Total liabilitiesAt period end2022-12-31MXN 19.64bnifrs-full:Liabilities
Shareholders' equityAt period end2022-12-31MXN 47.96bnifrs-full:EquityAttributableToOwnersOfParent
Shares outstandingAt period end2022-12-31462,135,888 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001213900-23-034743. Last ingested by Listed: Oct 29, 2026, 06:05 ET. Listed shows no prices and gives no investment advice.